Skip to Content
Merck
CN

Radioiodine retention on percutaneous endoscopic gastrostomy tubes.

The British journal of radiology (2012-03-30)
J W Scuffham, K A Wood, R P Clauss, S A Kilfeather, P J Hinton
ABSTRACT

An 80-year-old male with recurrent thyroid cancer and a percutaneous endoscopic gastrostomy (PEG) tube in situ was referred for radioiodine therapy and was administered 5510 MBq I-131 sodium iodide intravenously. Sequential whole-body images taken over the subsequent 7 days for dosimetric evaluation revealed an area of persistent high uptake in the abdomen. Delayed imaging with single photon emission CT/CT at 15 days post administration revealed this uptake to be at the junction of the PEG tube with the anatomically normal stomach wall. We hypothesise that the PEG tube became contaminated by radioiodine secreted in the gastric mucosa during therapy and this radioactivity subsequently decayed with an increased effective half-life relative to the stomach, leading to the apparent hot spot.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium iodide, ReagentPlus®, ≥99%
Sigma-Aldrich
Sodium iodide, puriss., meets analytical specification of Ph. Eur., BP, USP, 99-100.5% (calc. to the dried substance)
Sigma-Aldrich
Sodium iodide, ACS reagent, ≥99.5%
Sigma-Aldrich
Sodium iodide, 99.999% trace metals basis
Sigma-Aldrich
Sodium iodide, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
Sodium iodide, ≥99.99% trace metals basis